Jaguar health receives notice of allowance for u.s. patent for lead fda approved drug crofelemer

Company's ip estate includes approximately 200 patents issued and pending san francisco, ca / accesswire / february 23, 2023 / jaguar health, inc. (nasdaq:jagx) ("jaguar" or the "company") today announced that the company has received a notice of allowance from the u.s. patent and trademark office (uspto) for u.s. patent application no. 16/617,466, titled methods and compositions for treating bile acid diarrhea, diarrhea associated with small intestine resection or gallbladder removal, and short bowel syndrome.
JAGX Ratings Summary
JAGX Quant Ranking